PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 2328476

Adjuvant systemic therapy.

P P Carbone·D W Nixon·J Fennelly·E Greenberg·I C Henderson·G Hortobagyi·B J Kennedy·N Trainin·E F Scanlon
View original source ↗Export metadata ↓

Abstract

The source did not provide an abstract. Follow the original record for more information.

Explore related subjects

Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCombined Modality TherapyFemaleHumansJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

P P Carbone, D W Nixon, J Fennelly, E Greenberg, I C Henderson, G Hortobagyi, B J Kennedy, N Trainin, E F Scanlon. 1990-05-01. Adjuvant systemic therapy.. https://doi.org/10.1002/1097-0142(19900501)65%3A9%2B%3C2108%3A%3Aaid-cncr2820651404%3E3.0.co%3B2-f

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1992

Adjuvant therapy for primary breast cancer in a female patient affected by autoimmune liver disease: does it cure breast cancer and primary biliary cirrhosis?

Polychemotherapy (CMF or CMF-like regimens) is the treatment of choice in premenopausal breast cancer patients with 1-3 positive nodes. In clinical practice, patients with abnormal biochemical tests of liver function are usually excluded from this potentially curative methotrexate-containing regimen in order to avoid worsening of hepatic damage. On the other hand, recent reports have shown a beneficial effect of methotrexate in a particular autoimmune liver disease such as primary biliary cirrhosis. We discuss the case of a female patient with breast cancer and primary biliary cirrhosis whose biochemical tests of liver function and the titer of antimitochondrial antibody persistently improved after treatment with 3 cycles of CMF. In conclusion, we suggest that the CMF regimen is potentially useful in patients with breast cancer and primary biliary cirrhosis.

Antineoplastic Combined Chemotherapy Protocols↗